Longeveron (NASDAQ:LGVN) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Longeveron (NASDAQ:LGVN) to a hold rating in a research report sent to investors on Saturday.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Longeveron in a research report on Thursday, January 22nd. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $3.00.

Longeveron Trading Down 5.5%

Shares of NASDAQ:LGVN opened at $1.04 on Friday. The business’s 50-day moving average is $0.83 and its 200 day moving average is $0.72. The company has a debt-to-equity ratio of 0.03, a current ratio of 1.33 and a quick ratio of 1.33. Longeveron has a 1 year low of $0.48 and a 1 year high of $1.83. The firm has a market capitalization of $24.20 million, a P/E ratio of -0.81 and a beta of -0.18.

Longeveron (NASDAQ:LGVN) last issued its quarterly earnings results on Tuesday, March 17th. The company reported ($0.22) earnings per share for the quarter, topping the consensus estimate of ($0.42) by $0.20. Longeveron had a negative return on equity of 199.79% and a negative net margin of 1,893.58%.The business had revenue of $0.37 million during the quarter, compared to the consensus estimate of $0.11 million. On average, research analysts predict that Longeveron will post -0.62 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Longeveron

A hedge fund recently bought a new stake in Longeveron stock. XTX Topco Ltd purchased a new stake in shares of Longeveron Inc. (NASDAQ:LGVN) during the 2nd quarter, according to the company in its most recent filing with the SEC. The fund purchased 48,003 shares of the company’s stock, valued at approximately $62,000. XTX Topco Ltd owned about 0.32% of Longeveron as of its most recent filing with the SEC. 10.01% of the stock is owned by institutional investors.

About Longeveron

Longeveron Inc is a clinical-stage biotechnology company focused on the development and commercialization of allogeneic cellular therapies designed to address aging-related and inflammatory conditions. The company’s primary therapeutic candidate, Lomecel-B, is an off-the-shelf mesenchymal stem cell product derived from bone marrow. Through its proprietary manufacturing process, Longeveron aims to produce a consistent, scalable cell therapy platform with potential applications in multiple disease areas.

Longeveron’s pipeline encompasses several ongoing and completed clinical studies.